EP Patent

EP4430191A2 — Oligonucleotides for sod1 modulation

Assigned to University of Massachusetts Boston · Expires 2024-09-18 · 2y expired

What this patent protects

This disclosure relates to novel SOD1 targeting sequences. Novel SOD1 targeting oligonucleotides for the treatment of SOD1-related familial amyotrophic lateral sclerosis (ALS).

USPTO Abstract

This disclosure relates to novel SOD1 targeting sequences. Novel SOD1 targeting oligonucleotides for the treatment of SOD1-related familial amyotrophic lateral sclerosis (ALS).

Drugs covered by this patent

Patent Metadata

Patent number
EP4430191A2
Jurisdiction
EP
Classification
—
Expires
2024-09-18
Drug substance claim
No
Drug product claim
No
Assignee
University of Massachusetts Boston
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.